New Opportunities in the Biosimilars Market

17 December 2019
Pharma

The biosimilars market size is one that’s in constant flux, as new regulations, trade agreements, scientific discoveries, and other factors affect the marketplace on a daily basis. This can make it difficult for business owners and drug manufacturers to predict major market changes and make long-term decisions. That’s why being armed with expert insight can be of great help.

For decades, the experts from Visiongain have been compiling all the latest biosimilar market data into their yearly reports with forecasts and analysis. They’ve shared some of that insight with you below. Here are some of today’s newest and most exciting opportunities for stakeholders in the biosimilars market.

Turkey Prepares to Export Biosimilars in the Coming Years

One big change in the biosimilars market size in the years ahead will be that Turkey has begun preparing to export drugs to the UK over the next two years. Recently, Iranian biosimilars maker CinnaGen Pharmaceuticals opened a new plant in Çerkezköy, Turkey, to produce rare drugs that will reportedly save Turkey $150 million on imports the first year it’s opened. In addition to being able to export drugs to Europe after only two years, CinnaGen Pharmaceuticals representatives also stated the company has signed agreements with several countries, including Qatar, Ecuador, and Algeria.

Korean Biologics firm Receives Approval for Monoclonal Antibody Substance

Samsung BioLogics, one of South Korea’s leading biologics manufacturers, recently received a thumbs up from the Food & Drug Administration (FDA) to continue producing a monoclonal antibody (mAb), the first product produced at one of three new plants it recently built. To date, the FDA and Europe have already approved the company to produce two finished products, this will be its third. Since expanding to the biosimilars market from the chemical manufacturing fields, Samsung BioLogics has become one of the fastest-growing biosimilars companies in the world.

China Biotech Company Makes Huge Progress in Treating Multiple Myeloma

Another big change that will affect the biosimilar market size in the years ahead is the recent development of multiple myeloma treatments. Chinese firm I-Mab Biopharma recently got the green light to expand its ongoing Phase II and III clinical trials for its drug TJ202/MOR202l, which is a monoclonal antibody.

Let Visiongain help you excel in the biosimilars market

For more in-depth information and analysis of the biosimilars market, contact the team from Visiongain today by visiting us online or calling +44 (0) 20 7549 9987. In addition to our biosimilar market size reports, we offer in-depth analysis for more than 18 industry verticals, with over 1,500 reports available.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever